Print

Lay Description

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of radiation therapy (RT) and concurrent temozolomide (TMZ) chemotherapy for patients with newly diagnosed glioblastoma (GB).

Category

  • Cancers and Other Neoplasms
IRB Number
STUDY00001094
NCT Number
NCT04752813

Eligibility

Eligible Ages
18
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Patients with newly diagnosed pathologically verified GB (by the World Health Organization 2021 criteria or using molecular features defined in C-IMPACT, update 6) (26) with any evidence of residual disease (enhancing or fast fluid-attenuated inversion-recovery [FLAIR]).
2. No prior RT, chemotherapy, immunotherapy, or targeted agents administered specifically for the lesion being treated.

Exclusion Criteria

History of clinically significant tumor-related cerebral hemorrhage.
2. Patients with multicentric disease defined by tumors which have multiple discrete areas of contrast-enhancing tumor without connecting T2/FLAIR signal abnormality.
3. Patients with diffuse leptomeningeal disease.
4. Patients who are not eligible for definitive surgical resection.
5. Patients on decadron daily dosing more than 2 mg.

Study Design

Arm Groups

Study Contact

Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu

Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu

Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu

Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu

Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu

Principal Investigator
Andrew Brenner